Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Optimising the vaccine strategy of BCG, ChAdOx1 85A, and MVA85A for tuberculosis control.

Journal article

Wajja A. et al, (2024), Lancet Infect Dis

Exploring the Ethics of Tuberculosis Human Challenge Models

Journal article

Rohrig A. et al, (2023), Journal of Medical Ethics

Improving TB vaccine trial efficiency: A tough nut to crack.

Journal article

Mcshane H., (2023), J Infect Dis

A five-antigen Esx-5a fusion delivered as a prime-boost regimen protects against M.tb challenge.

Journal article

Stylianou E. et al, (2023), Front Immunol, 14

BCG: Past, Present and Future Direction

Chapter

Morrison H. and McShane H., (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 171 - 195

Healthy volunteer symptom profile following research bronchoscopy

Conference paper

Morrison H. et al, (2023), EUROPEAN RESPIRATORY JOURNAL, 62

The VALIDATE Network: Accelerating Vaccine Development for Tuberculosis, Leishmaniasis, Melioidosis and Leprosy

Chapter

Vermaak S. et al, (2023), Vaccines for Neglected Pathogens: Strategies, Achievements and Challenges: Focus on Leprosy, Leishmaniasis, Melioidosis and Tuberculosis, 11 - 25

Tuberculosis vaccines in the era of Covid-19 - what is taking us so long?

Journal article

Dockrell HM. and McShane H., (2022), EBioMedicine, 79

Challenges in Developing a Controlled Human Tuberculosis Challenge Model.

Journal article

Jackson S. and McShane H., (2022), Curr Top Microbiol Immunol

Load More